NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement option grants covering an aggregate of 40,000 ordinary shares to two non‑executive new hires under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options carry an exercise price of $39.61, equal to the closing Nasdaq price on December 1, 2025 (grant date). The shares subject to the options vest over four years: 25% on the one‑year anniversary of each vesting commencement date, then the balance in 36 equal monthly installments, subject to continued service. The options are governed by the 2024 Inducement Plan and individual option award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NAMS
+1.39%
+1.39%Session close to close
In the Dec 8 session, NAMS gained 1.39%, reflecting a mild positive market reaction.
This announcement details a routine inducement grant of 40,000 options under the 2024 Inducement Pla...
Analysis
This announcement details a routine inducement grant of 40,000 options under the 2024 Inducement Plan, with an exercise price of $39.61 and four-year vesting. It follows a similar inducement grant disclosed in November 2025, as well as recent clinical, conference, and financial updates that previously saw positive share reactions. Investors may monitor future grants, overall equity compensation usage, and upcoming clinical or regulatory milestones to understand how dilution and execution progress balance over time.
Key Figures
Inducement options granted:40,000 sharesOption exercise price:$39.61Current share price:$35.97+5 more
8 metrics
Inducement options granted40,000 sharesAggregate inducement share options to two non-executive new hires
Option exercise price$39.61Exercise price equal to Dec 1, 2025 Nasdaq closing price
Current share price$35.97Pre-news closing price versus 52-week high of $42.00
Price vs 52-week high-14.36%Distance from 52-week high prior to this news
Price vs 52-week low155.83%Gain versus 52-week low prior to this news
Vesting period4 years25% after one year, then 36 equal monthly installments
Initial vesting cliff25%Vests on one-year anniversary of vesting commencement date
Monthly installments36 installmentsRemaining options vest in 36 equal monthly tranches
Caristo selected as imaging core lab for REMBRANDT cardiovascular trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Across the last five news items, NAMS shares showed consistently positive 24-hour reactions, including to conference participation, trial updates, earnings, and prior inducement grants.
Recent Company History
Over the past six months, NewAmsterdam reported multiple milestones. Conference and medical meeting participation in October–November 2025 around its BROOKLYN, BROADWAY, TANDEM, and REMBRANDT programs all saw positive next-day price reactions, as did the Q3 2025 earnings and corporate update with $756.0M cash and a $72.0M net loss. A prior inducement grant announcement on Nov 7, 2025 also coincided with a positive move, providing context for today’s new inducement grants.
Key Terms
nasdaq listing rule 5635(c)(4), exercise price, vesting, option award agreement
4 terms
nasdaq listing rule 5635(c)(4)regulatory
"approved the grant of inducement share options ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"The share options have an exercise price per share equal to $39.61, which represents the closing market price..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
option award agreementfinancial
"The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement..."
A written contract that grants an individual the right to buy company shares at a set price under specific conditions, like how many options they get, when they can exercise them, and when they expire. Think of it like a ticket that becomes valid only after certain milestones; it matters to investors because these agreements affect how many shares may enter the market, management incentives, and a company’s future earnings per share and dilution.
NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 40,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to $39.61, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on December 1, 2025, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.
About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
